Publications by authors named "Johanna Latzka"
On behalf of the EORTC Cutaneous Lymphoma Tumours Group (EORTC-CLTG) and following up on earlier versions published in 2006 and 2017 this document provides an updated standard for the treatment of mycosis fungoides and Sézary syndrome (MF/SS). It considers recent relevant publications and treatment options introduced into clinical practice after 2017. Consensus was established among the authors through a series of consecutive consultations in writing and a round of discussion.
View Article and Find Full Text PDFMycosis fungoides and Sézary syndrome are the most important representatives of the heterogeneous group of cutaneous T-cell lymphomas. The diseases are rare and the diagnosis, which always requires a clinical-pathological correlation, is often delayed, especially in early forms of mycosis fungoides. The prognosis of mycosis fungoides depends on its stage and is usually favorable in the early stages.
View Article and Find Full Text PDFArticle Synopsis
- - Recurrent gain-of-function mutations in transcription factors are prevalent in hematopoietic malignancies, particularly in mature T-cell and natural killer-cell neoplasms like peripheral T-cell lymphoma (PTCL), which currently lack targeted therapies
- - Researchers created transgenic mice with heightened STAT5A or STAT5B activity, and only those with high levels developed a fatal disease similar to human PTCL, characterized by extensive CD8 T-cell expansion and organ infiltration
- - Analysis showed that increased STAT5 activity correlates with different PTCL subtypes, suggesting that JAK/STAT pathways are promising therapeutic targets, as both JAK inhibitors and selective STAT5 inhibitors effectively induced cell death in T-cell neoplasia*.